<DOC>
	<DOCNO>NCT00263744</DOCNO>
	<brief_summary>The primary objective study describe safety 40 mg MEDI-517 , control aluminum hydroxide , give healthy adult woman evidence HPV-16 and/or HPV-18 DNA detect cervical brushing .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity MEDI-517P Healthy Adult Female Volunteers Who Are HPV-16 HPV-18 DNA Positive</brief_title>
	<detailed_description />
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Female 18 30 year age ( must reach 31st birthday ) Unless previously surgically sterilize , agree use effective method birth control ( e.g. , abstinence , intrauterine contraceptive device , oral contraceptive , diaphragm condom combination contraceptive jelly , cream foam , Norplant® DepoProvera® ) begin 30 day first study injection continue 60 day final study injection Healthy medical history physical examination Cervical specimen positive HPV16 and/or HPV18 DNA use Digene Hybrid Capture® II HPV test within 21 day study entry Cervical cytology Pap smear either normal great ASCUS AGCUS , use Cytyc ThinPrep® Pap Test , within 21 day study entry ( normal Pap smear must also adequate interpretation ; Pap smear normal inadequate interpretation must repeat ) . Those volunteer ASCUS AGCUS must clinical evaluation colposcopy within previous month show evidence CIN SIL . No evidence anogenital HPV lesion physical finding suggestive gynecologic pathogen pelvic examination within 21 day study entry Agrees experimental therapy vaccine 30 day last study injection Written inform consent obtain volunteer Acute illness fever ( oral temperature ³99.5°F [ 37.5°C ] ) start study History clinical manifestation significant medical psychiatric disorder Pregnant lactating Use immunosuppressive medication ( inhaled topical corticosteroid permit ) within previous 90 day history immunodeficiency History cancer History alcohol drug abuse within past 2 year At screening ( must within 21 day study entry ) following : hemoglobin &lt; 11 gm/dL ; white blood cell count &lt; 4000/mm3 ; platelet count &lt; 120,000/mm3 ; AST , ALT , creatinine &gt; 1.5x upper limit normal laboratory question ; abnormal laboratory value screen panel opinion principal investigator judge clinically significant Receipt immunoglobulin blood product within 90 day prior study entry History Pap smear severe ASCUS AGCUS Positive test hepatitis C antibody , hepatitis B surface antigen , HIV1 antibody Any prior receipt vaccine therapy ( experimental otherwise ) treatment prophylaxis genital wart papillomavirus relate condition . Any treatment genital wart papillomavirus relate condition within six month randomization ( local therapy common skin and/or plantar wart allow ) Prior receipt vaccine contain monophosphoryl lipid A SBAS4 adjuvant ( vaccine currently license contain ) Receipt experimental vaccine within 90 day prior entry study Receipt experimental drug therapy within 30 day five halflives experimental drug ( halflife know ) , whichever long</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>